Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Revenue (2016 - 2025)

Historic Revenue for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $264.0 million.

  • Arrowhead Pharmaceuticals' Revenue rose 1046132.0% to $264.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 4353924.0%. This contributed to the annual value of $829.4 million for FY2025, which is 2325815.26% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Revenue stood at $264.0 million for Q4 2025, which was up 1046132.0% from $256.5 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Revenue high stood at $542.7 million for Q1 2025, and its period low was $2.5 million during Q4 2024.
  • Moreover, its 5-year median value for Revenue was $32.8 million (2021), whereas its average is $99.9 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 9432.26% in 2023, then surged by 1046132.0% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Revenue stood at $27.4 million in 2021, then skyrocketed by 127.95% to $62.5 million in 2022, then crashed by 94.32% to $3.6 million in 2023, then fell by 29.6% to $2.5 million in 2024, then skyrocketed by 10461.32% to $264.0 million in 2025.
  • Its last three reported values are $264.0 million in Q4 2025, $256.5 million for Q3 2025, and $27.8 million during Q2 2025.